J&J: A 100-Year-Old Dividend King That Keeps Delivering

Few companies have survived as many economic cycles, market crashes, technological changes, and shifts in consumer behavior as Johnson & Johnson.

For more than a century, J&J has built a reputation around healthcare, innovation, stability, and shareholder returns. But in 2026, the company looks quite different from the consumer-health giant many investors remember.

Following the separation of Kenvue, Johnson & Johnson is now more focused on Innovative Medicine and MedTech—two businesses positioned around pharmaceuticals, medical devices, surgery, cardiovascular care, oncology, immunology, neuroscience, and vision.

And despite the company's enormous size, J&J is still growing.

In the second quarter of 2026, Johnson & Johnson generated $25.3 billion in sales, up 6.6% year over year, while management raised its full-year outlook and said the company was on track to surpass $100 billion in annual revenue for the first time in its 140-year history. (Johnson & Johnson Investor Relations)

At the same time, J&J raised its dividend for the 64th consecutive year, lifting the quarterly payout to $1.34 per share. (Johnson & Johnson Investor Relations)

So, what makes this healthcare giant such a compelling dividend stock?

A Dividend Record Few Companies Can Match

The simplest reason investors continue to watch J&J is its dividend history.

In April 2026, the company announced its 64th consecutive annual dividend increase. The latest increase raised the quarterly dividend by 3.1%, from $1.30 to $1.34 per share, giving the stock an indicated annual dividend of $5.36 per share. (Johnson & Johnson Investor Relations)

That kind of consistency is extremely difficult to achieve.

Companies can maintain dividends during good economic periods. The real test comes during recessions, financial crises, inflation shocks, pandemics, and periods of weak consumer spending.

J&J has built a business designed around products and services that people need regardless of the economic environment.

People may postpone buying a new television or automobile.

They are much less likely to postpone necessary medical treatment.

That gives healthcare companies like J&J a degree of defensive strength.

J&J Is No Longer the Same Company

One of the most important changes investors should understand is that Johnson & Johnson is now more focused than it was several years ago.

The company completed the separation of its consumer-health business into Kenvue, leaving J&J primarily focused on two major segments:

Innovative Medicine

and

MedTech.

This creates a more concentrated healthcare business.

Innovative Medicine includes areas such as oncology, immunology, neuroscience, and other pharmaceutical categories.

MedTech includes cardiovascular technology, surgery, orthopedics, vision, and other medical-device businesses.

The result is a company that is increasingly focused on medical innovation rather than everyday consumer products.

Innovative Medicine Is Driving Growth

Pharmaceutical innovation is one of the biggest reasons investors remain interested in J&J.

The company has a broad portfolio of established drugs as well as a significant development pipeline.

In 2025, J&J's Innovative Medicine sales grew 5.3% operationally. Growth was driven by medicines including DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE, TREMFYA, SIMPONI/SIMPONI ARIA, and SPRAVATO. (Johnson & Johnson Investor Relations)

This matters because pharmaceutical companies constantly face a major challenge:

What happens when a blockbuster drug loses exclusivity?

J&J has experienced this challenge with STELARA, whose sales were pressured by competition and loss of exclusivity.

But the company's strategy is to replace declining products with newer medicines.

That creates a continuous cycle of research, approvals, commercialization, and eventually new revenue streams.

Oncology Could Be a Major Growth Engine

Cancer treatment is one of the most important areas in modern medicine, and J&J has built a substantial oncology portfolio.

Drugs such as DARZALEX and CARVYKTI have become important parts of the company's growth strategy.

The company is also investing in new treatments and combinations designed to address cancer at different stages.

This is important from an investment perspective because successful pharmaceutical products can generate billions of dollars in revenue.

But they can also create enormous value beyond their initial indication.

A successful cancer therapy may eventually be tested in additional patient populations or combined with other treatments.

That gives successful drug platforms the potential to remain commercially important for many years.

Immunology Remains Important

Immunology is another major part of J&J's pharmaceutical business.

TREMFYA, for example, is an important product in the company's strategy.

The challenge is that immunology is highly competitive.

J&J has to compete with major pharmaceutical companies developing treatments for conditions such as psoriasis and psoriatic arthritis.

That means innovation is critical.

The good news for investors is that J&J isn't relying on a single product.

It has a diversified pharmaceutical portfolio across multiple therapeutic areas.

MedTech Gives J&J Something Different

Unlike pure pharmaceutical companies, J&J also has a massive medical-device business.

This is a major advantage because medical devices create a different type of healthcare growth opportunity.

J&J's MedTech business includes cardiovascular technology, surgery, vision, and other medical applications.

In 2025, MedTech worldwide operational sales increased 5.4%, with growth driven by electrophysiology products, Abiomed in cardiovascular care, and wound-closure products in general surgery. (Johnson & Johnson Investor Relations)

The company is also continuing to invest in innovative surgical technology.

For example, J&J is developing its OTTAVA robotic surgical system, which could eventually give the company another opportunity in the growing robotic-surgery market. (Johnson & Johnson Investor Relations)

Cardiovascular Technology Could Become Increasingly Important

Heart disease remains one of the world's biggest healthcare challenges.

That creates a long-term opportunity for medical-device companies.

J&J has expanded its cardiovascular capabilities through acquisitions and product development, including its Abiomed business.

The company is also advancing technologies related to electrophysiology and other cardiovascular procedures.

This is a different growth model from pharmaceuticals.

A medical device may generate recurring demand as hospitals purchase equipment, physicians adopt new procedures, and patient populations grow.

The Financial Numbers Tell an Interesting Story

J&J's 2025 results demonstrated that the company still has substantial scale.

Full-year 2025 sales reached approximately $94.2 billion, up 6.0% from the previous year.

Adjusted EPS increased 8.1% to $10.79, while the company estimated approximately $19.7 billion of free cash flow. (Johnson & Johnson Investor Relations)

Then came an even stronger 2026 outlook.

After reporting second-quarter results, J&J raised its estimated 2026 reported sales outlook to $101.1 billion at the midpoint and increased adjusted EPS guidance to $11.68 at the midpoint. (Johnson & Johnson Investor Relations)

That suggests the company is entering a new phase of growth rather than simply defending its legacy business.

The $100 Billion Milestone Matters

J&J's expected move beyond $100 billion in annual revenue is symbolically important.

For a company with roughly 140 years of history, reaching a new revenue milestone demonstrates how large the underlying healthcare opportunity has become.

But more importantly, investors should focus on what is driving that growth.

The company isn't simply increasing prices.

It is attempting to grow through:

• New pharmaceutical approvals

• Expansion of existing medicines

• Medical-device innovation

• Acquisitions

• International markets

• Surgical technology

• Cardiovascular products

• Oncology treatments

• Neuroscience therapies

That provides multiple potential growth engines.

The Biggest Risk: Patent Expirations

Every major pharmaceutical company faces the same problem.

Eventually, successful drugs lose patent protection.

When that happens, generic and biosimilar competitors can enter the market.

J&J's STELARA experience demonstrates exactly why investors need to watch patent cycles.

The company has to continuously develop new products to replace declining revenue.

That makes the pipeline incredibly important.

A pharmaceutical company's future isn't determined only by today's sales.

It is determined by what is currently in clinical trials, what is awaiting approval, and which new products can become tomorrow's blockbusters.

Litigation Remains a Risk

J&J has also faced significant legal challenges over the years.

The company's talc-related litigation has been one of the most closely watched issues by investors.

Legal outcomes can be unpredictable, and large settlements or judgments can affect earnings and cash flow.

This is one reason investors shouldn't look at J&J solely through its dividend history.

A strong dividend is attractive, but legal liabilities remain an important risk factor.

J&J's Size Is Both a Strength and a Weakness

At more than $100 billion in annual revenue, J&J has enormous financial resources.

It can spend billions on research and development.

It can acquire promising healthcare companies.

It can invest in medical technology.

It can market drugs globally.

And it can distribute products through a massive international network.

But size can also make rapid growth difficult.

A smaller biotechnology company might double its revenue by launching one successful medicine.

For J&J, a new $1 billion product is meaningful—but relatively small compared with its overall business.

Therefore, investors shouldn't expect J&J to grow like a young technology company.

Its attraction is different.

It is about steady compounding, diversification, innovation, and shareholder returns.

Why Dividend Investors Like J&J

J&J's dividend story is particularly attractive because the company doesn't operate in only one healthcare category.

It has multiple revenue streams.

If one pharmaceutical product struggles, another may grow.

If a particular medical-device category slows, another may accelerate.

That diversification can help stabilize cash flow.

The dividend also isn't the only way shareholders can benefit.

If earnings grow and the company continues increasing its dividend, investors can potentially receive both income and capital appreciation.

That combination is one reason J&J has remained popular among long-term investors.

The Future Could Be More Innovative Than Defensive

It would be easy to describe J&J as a conservative dividend stock.

But that description may underestimate its growth potential.

The company is investing in areas such as:

Oncology

Neuroscience

Immunology

Cardiovascular medicine

Robotic surgery

Vision

Advanced medical devices

These are areas where technological innovation can create entirely new markets.

J&J's strategy is increasingly centered around medical breakthroughs rather than simply selling established healthcare products.

Could J&J Become an AI Healthcare Player?

Artificial intelligence is also becoming increasingly important in healthcare.

AI can potentially improve drug discovery, clinical-trial design, diagnostics, medical imaging, personalized treatment, and surgical technologies.

J&J doesn't need to become an AI software company to benefit.

Instead, it can integrate AI into its pharmaceutical research and medical-device businesses.

For example, AI-assisted surgical systems could potentially improve precision and efficiency.

AI could also help researchers analyze massive datasets when developing new treatments.

This creates another long-term technological opportunity.

The Valuation Question

The biggest question for investors isn't whether J&J is a good company.

It clearly has many characteristics of a high-quality business.

The question is:

How much are investors paying for that quality?

A premium valuation can make even a great company a mediocre investment if future growth fails to justify the price.

Investors should therefore examine the stock's price-to-earnings ratio, dividend yield, expected earnings growth, free cash flow, debt levels, and pharmaceutical pipeline before buying.

J&J's defensive characteristics can be valuable, but investors shouldn't assume that the stock will outperform in every market environment.

Final Verdict

Johnson & Johnson's story in 2026 is much more than a story about a century-old healthcare company paying dividends.

It is a story about transformation.

The company has moved beyond its traditional consumer-health identity and is now concentrated on Innovative Medicine and MedTech.

Its pharmaceutical portfolio provides exposure to oncology, immunology, neuroscience, and other high-value medical categories.

Its MedTech business provides exposure to cardiovascular care, surgery, vision, and other medical technologies.

And its dividend continues to provide one of the company's strongest attractions.

The latest increase marked the 64th consecutive year of dividend growth, bringing the annualized dividend to $5.36 per share. (Johnson & Johnson Investor Relations)

Meanwhile, J&J's second-quarter 2026 performance led management to raise its full-year outlook, with the company expecting approximately $101.1 billion in reported sales at the midpoint and adjusted EPS of $11.68. (Johnson & Johnson Investor Relations)

That combination is what makes J&J interesting.

It offers the stability of a healthcare giant with the growth potential of an innovative pharmaceutical and medical-device company.

Of course, risks remain.

Patent expirations, pharmaceutical competition, regulatory changes, litigation, clinical failures, and valuation can all affect returns.

But for investors seeking a long-term healthcare holding with a remarkable dividend history, diversified operations, and multiple avenues for future growth, J&J remains one of the most interesting names in the market.

The company may be more than 100 years old, but its investment story is still evolving.

And if Johnson & Johnson can continue turning medical innovation into growing cash flow, the Dividend King may have plenty of chapters left to write.

Disclaimer: This article is for informational and educational purposes only and should not be considered financial advice. Johnson & Johnson's stock can be affected by pharmaceutical competition, patent expirations, clinical-trial outcomes, regulation, litigation, acquisitions, and broader market conditions. Investors should conduct their own research and consider their financial goals and risk tolerance before making investment decisions.